- Trials with a EudraCT protocol (84)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
84 result(s) found for: Systemic scleroderma.
Displaying page 1 of 5.
EudraCT Number: 2006-007091-15 | Sponsor Protocol Number: CSTI571ENL18 | Start Date*: 2007-09-03 | |||||||||||
Sponsor Name:ErasmusMC | |||||||||||||
Full Title: Glivec (imatinib mesylate) in systemic sclerosis, a pilot study | |||||||||||||
Medical condition: systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007180-16 | Sponsor Protocol Number: RITIS | Start Date*: 2009-05-13 | |||||||||||
Sponsor Name:LUMC | |||||||||||||
Full Title: INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMA | |||||||||||||
Medical condition: systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002015-38 | Sponsor Protocol Number: ISD002-P144-07 | Start Date*: 2007-08-23 | |||||||||||
Sponsor Name:ISDIN | |||||||||||||
Full Title: "ENSAYO CLÍNICO MULTICÉNTRICO, FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO INTRAINDIVIDUALMENTE CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE P144 EN EL TRATAMIENTO TÓPICO DE LA FIBROSIS ... | |||||||||||||
Medical condition: "FIBROSIS CUTÁNEA DE PACIENTES CON ESCLEROSIS SISTÉMICA" "SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS" | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) HU (Completed) GB (Completed) DE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003122-24 | Sponsor Protocol Number: DISS01 | Start Date*: 2008-04-09 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Daval International Limited | ||||||||||||||||||||||||||||||||||||||
Full Title: A Double-Blind Placebo-Controlled Pilot Study of the Safety and Tolerability of AIMSPRO in established Diffuse Cutaneous Systemic Sclerosis | ||||||||||||||||||||||||||||||||||||||
Medical condition: Diffuse Cutaneous Systemic Sclerosis | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005018-39 | Sponsor Protocol Number: TDE-DU-201 | Start Date*: 2009-03-05 | ||||||||||||||||
Sponsor Name:United Therapeutics Corporation | ||||||||||||||||||
Full Title: DISTOL-1:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: A randomized, double-blind, placebo controlled, multicenter study | ||||||||||||||||||
Medical condition: Systemic Sclerosis, scleroderma digital ulcers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006978-15 | Sponsor Protocol Number: TDE-DU-202 | Start Date*: 2009-03-05 | ||||||||||||||||
Sponsor Name:United Therapeutics Corporation | ||||||||||||||||||
Full Title: DISTOL-EXT:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: An open-label multicenter extension study | ||||||||||||||||||
Medical condition: Systemic Sclerosis, scleroderma digital ulcers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001265-28 | Sponsor Protocol Number: ISD003-P144-08 | Start Date*: 2008-06-17 | |||||||||||
Sponsor Name:ISDIN | |||||||||||||
Full Title: “Estudio abierto de extensión con P144 para la ampliación del tratamiento tópico de la fibrosis cutánea de pacientes con esclerosis sistémica previamente tratados en el ensayo ISD002-P144-07" “Op... | |||||||||||||
Medical condition: "Fibrosis cutánea de pacientes con esclerosis sistémica" "Skin fibrosis in patients with systemic sclerosis" | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) HU (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017869-27 | Sponsor Protocol Number: TERSSC-001 incl. Amendment 1 | Start Date*: 2010-09-23 | |||||||||||
Sponsor Name:University Hospital Zurich | |||||||||||||
Full Title: A dual-center, open-label Proof of Concept study to evaluate the efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis. | |||||||||||||
Medical condition: Diffuse scleroderma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005322-68 | Sponsor Protocol Number: farm 69j aj9 | Start Date*: 2007-10-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | |||||||||||||
Full Title: Low-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study | |||||||||||||
Medical condition: Systemic Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000230-33 | Sponsor Protocol Number: HYDROXYSSc | Start Date*: 2022-01-26 | |||||||||||||||||||||||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||||||||||||||||||||||
Full Title: A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc | |||||||||||||||||||||||||||||||||
Medical condition: Systemic Sclerosis (SSc) is a rare and orphan disease (DPCM 12 gennaio 2017-GU SG n°65-S.O. n°15 - 18/03/2017), characterized by immunological, vascular and fibrotic abnormalities. The estimated in... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003403-66 | Sponsor Protocol Number: 1199.225 | Start Date*: 2017-11-06 | |||||||||||||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim bv | |||||||||||||||||||||||||||||||||
Full Title: An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) | |||||||||||||||||||||||||||||||||
Medical condition: Systemic Sclerosis associated Interstitial Lung Disease | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) ES (Completed) PT (Completed) GB (GB - no longer in EU/EEA) FR (Completed) DK (Completed) BE (Completed) AT (Completed) CZ (Completed) GR (Completed) SE (Completed) NO (Completed) FI (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005116-21 | Sponsor Protocol Number: CER-FT011-SSc01 | Start Date*: 2021-09-27 | |||||||||||
Sponsor Name:Certa Therapeutics Pty Ltd | |||||||||||||
Full Title: A phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in participants with diffuse systemic sclerosis | |||||||||||||
Medical condition: diffuse systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001667-44 | Sponsor Protocol Number: 11575705 | Start Date*: 2011-06-28 | ||||||||||||||||
Sponsor Name:Active Biotech AB | ||||||||||||||||||
Full Title: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod) | ||||||||||||||||||
Medical condition: Systemic Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001617-27 | Sponsor Protocol Number: IVA_01_337_HSSC_15_001 | Start Date*: 2015-09-18 | ||||||||||||||||
Sponsor Name:Inventiva SAS | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis | ||||||||||||||||||
Medical condition: Systemic sclerosis (scleroderma) (SSc) is a chronic connective tissue disorder of unknown aetiology characterized by widespread microvascular damage and excessive deposition of collagen in the skin... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) ES (Completed) GB (Completed) DE (Completed) NL (Completed) SI (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006035-32 | Sponsor Protocol Number: 2300/2007 | Start Date*: 2007-11-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
Full Title: Assessment of endothelial function and vasal response in patients with Systemic Sclerosis and Hypercholesterolemia, before and after simvastatin treatment. | |||||||||||||
Medical condition: Systemic Sclerosis and Hypercholesterolemia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019977-14 | Sponsor Protocol Number: CILOS-RAY2010 | Start Date*: 2010-11-04 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA | |||||||||||||
Full Title: Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis | |||||||||||||
Medical condition: Patients affected by Systemic Sclerosis with Raynaud’s Phenomenon | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003836-31 | Sponsor Protocol Number: AGO/2006/007 | Start Date*: 2006-09-06 | |||||||||||
Sponsor Name:University Hospital Gent | |||||||||||||
Full Title: A protocol based treatment for early and severe systemic sclerosis with (anti-CD-20) rituximab | |||||||||||||
Medical condition: systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001369-34 | Sponsor Protocol Number: ACT12339 | Start Date*: 2012-10-26 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: Double-blind, randomized, 8-week placebo-controlled and 16-week open label extension study investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients with... | |||||||||||||
Medical condition: Systemic Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005230-20 | Sponsor Protocol Number: NOT AVAILABLE | Start Date*: 2006-07-14 | |||||||||||
Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS) | |||||||||||||
Full Title: EX VIVO EFFECT OF AMINAFTONE (CAPILLAREMA) ON THE ENDOTELIAL FUNCTION IN SYSTEMIC SCLEROSIS. Effetto ex vivo dell’aminaftone (Capillarema) sulla funzione endoteliale nella Sclerosi Sistemica | |||||||||||||
Medical condition: Variazione della gravita' del fenomeno di Raynaud misurata mediante diario dei sintomi e scala analogica visiva VAS ヨ Visual Analogic Scale (6). Variazione dello stato globale di malattia valutat... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000701-61 | Sponsor Protocol Number: BIRD-1 250705 | Start Date*: 2005-11-29 |
Sponsor Name:University College London | ||
Full Title: An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis | ||
Medical condition: Scleroderma renal crisis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
